PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(01): 2-3
DOI: 10.4103/0971-5851.203492
Editorial Commentary

Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology?

Sameer Rastogi
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi
,
Vineet Gupta
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
06. Juli 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:1629-37.
  • 2 Young RJ, Woll PJ. Eribulin in soft-tissue sarcoma. Lancet 2016;387:1594-6.
  • 3 Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine- reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
  • 4 Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: Importance, indications, and interpretation. Lancet 2005;365:176-86.
  • 5 Maggioni AP, Darne B, Atar D, Abadie E, Pitt B, Zannad F; 5th Cardiovascular Clinical Trialists Workshop. FDA and CPMP rulings on subgroup analyses. Cardiology 2007;107:97-102.
  • 6 Saad ED, Buyse M. Statistical controversies in clinical research: End points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol 2016;27:373-8.
  • 7 Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: Evaluation of progression-free survival, duration of disease control, and time to failure of strategy- An Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol 2011;29:4199-204.
  • 8 Morita S, Sakamaki K, Yin G. Detecting overall survival benefit derived from survival postprogression rather than progression-free survival. J Natl Cancer Inst 2015;107. pii:Djv133.